We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Synpromics, Sartorius Stedim Cellca Partner
News

Synpromics, Sartorius Stedim Cellca Partner

Synpromics, Sartorius Stedim Cellca Partner
News

Synpromics, Sartorius Stedim Cellca Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Synpromics, Sartorius Stedim Cellca Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Synpromics is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.

Cellca has developed the Cellca CHO Expression Platform, an efficient system for the production of biologicals using CHO (Chinese Hamster Ovary) cells consisting of a proprietary cell line, growth medium, expression cassettes and fed-batch process. Cellca has already successfully completed more than 40 customer projects using its system. Synpromics has developed a unique panel of CHO specific synthetic promoters, using its proprietary PromPT™ platform, designed and selected for optimised expression of recombinant proteins.

The use of these synthetic promoters is expected to result in shorter cell line development timelines and significantly enhanced yields of biological products. 

Dr David Venables, CEO of Synpromics, commented, “The majority of recombinant proteins, including monoclonal antibodies, are produced using the CHO system. We believe that the combination of Cellca’s CHO bioprocessing platform with Synpromics’ synthetic promoters will provide a much more efficient production system. We’re aiming for significantly higher levels of product being achieved which will increase capacity while reducing production costs.”

Dr. Christoph Zehe, Head of Technology Development of Cellca, added, “We are delighted to be working with Synpromics on this exciting project. We believe it will offer significant benefit to our clients in being able to provide a superior production system for biological products.”

Source:

Original story from Synpromics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines. 

Advertisement